Document Detail

Providing end-organ protection with renin-angiotensin system inhibition: the evidence so far.
MedLine Citation:
PMID:  16470078     Owner:  NLM     Status:  MEDLINE    
Much debate surrounds the question of the optimal therapeutic choices for medication to control blood pressure and reduce cardiovascular events. Experimental evidence suggests that drugs that block the renin-angiotensin system retard vascular disease through their direct ability to antagonize the effects of angiotensin II, which has vasoconstrictive, vascular proliferative, and atherosclerotic effects. It is not known how to separate the potential vascular protective effects of the drugs from their antihypertensive benefits. Clinical trial evidence indicates that achieved lower blood pressure goals almost always confer cardiovascular risk reduction advantages. There is also evidence, however, that successful antihypertensive regimens incorporating a renin-angiotensin system blocker, such as an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, provide more cardiovascular risk reduction benefit compared with regimens that do not incorporate a renin-angiotensin blocker. This includes composite or specific end points involving reduction of stroke, myocardial infarction, or development of end-stage renal disease.
Matthew R Weir
Related Documents :
15127878 - Renal vascular resistance and renin-angiotensin system in the pathogenesis of early hyp...
6352478 - Arterial wall uptake of renal renin and blood pressure control.
7020728 - Inappropriate renin secretion and abnormal cardiovascular reflexes in coarctation of th...
541038 - Changes in plasma norepinephrine, blood pressure and heart rate during physical activit...
23204588 - Comparison of single layer staple closure versus double layer hand-sewn closure for equ...
17767378 - Sevoflurane anesthesia decreases cardiac vagal activity and heart rate variability.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of clinical hypertension (Greenwich, Conn.)     Volume:  8     ISSN:  1524-6175     ISO Abbreviation:  J Clin Hypertens (Greenwich)     Publication Date:  2006 Feb 
Date Detail:
Created Date:  2006-02-10     Completed Date:  2007-08-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888554     Medline TA:  J Clin Hypertens (Greenwich)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  99-105; quiz 106-7     Citation Subset:  IM    
Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21202, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / pharmacology*,  therapeutic use
Angiotensin-Converting Enzyme Inhibitors / pharmacology*,  therapeutic use
Blood Pressure / drug effects
Cardiovascular Diseases / prevention & control*
Coronary Vessels / drug effects
Hypertension / drug therapy*
Kidney Failure, Chronic / prevention & control*
Renin-Angiotensin System / drug effects*
Risk Reduction Behavior
Treatment Outcome
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nut...
Next Document:  Management strategies for patients with hypertension and diabetes: why combination therapy is critic...